510(k) Report

510(k) · Cleared

Cleared

Aia-Pack CA 125

K990431510(k) TraditionalCleared Jun 3, 1999112-day reviewClass II21 CFR 866.6010

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Tosoh Medics, Inc. · LTK Test, Epithelial Ovarian Tumor-Associated Antigen (Ca125)

Cleared on Jun 3, 1999 after a 112-day review. FDA’s file for it is a 510(k) statement, which names no predicate. 2 later devices descend from it.

Decided
Jun 3, 1999
Review
112 days
Class
Class II
Product code
LTK
Recalls
None
Predicates
0

2 later devices descend from it, 1 citing it directly.

Descendants, by year cleared 2002: 1 descendant cleared2009: 1 descendant cleared1995200020052010201520202025
  1. This deviceK990431 Aia-Pack CA 125Tosoh Medics, Inc. · 1999
  2. Descendant · cites it directly · 1 of its ownK023891 ST Aia-Pack CA 125 Enzyme ImmunoassayTosoh Medics, Inc. · 2002
  3. Descendant · 2 generations on · 0 of its ownK080561 Vidas CA 125 II AssaybioMerieux, Inc. · 2009

Most influential descendants

Showing 2 of 2 · See all
  • K023891ST Aia-Pack CA 125 Enzyme ImmunoassayTosoh Medics, Inc. · 2002 · cites it directly1descendant
  • K080561Vidas CA 125 II AssaybioMerieux, Inc. · 2009 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K990431Aia-Pack CA 125Tosoh Medics, Inc.1999—
+1K023891ST Aia-Pack CA 125 Enzyme ImmunoassayTosoh Medics, Inc.2002—
+2K080561Vidas CA 125 II AssaybioMerieux, Inc.2009—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
200210
200910
FIG. 1 — Lineage of K990431, 1999–2009Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LTK? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LTK device

  1. #1 K240479 Access OV Monitorscore 7.3 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it? (2)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K023891ST Aia-Pack CA 125 Enzyme ImmunoassayTosoh Medics, Inc.20021

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K023891 (Tosoh Medics, Inc., 2002) has gone furthest, with 1 descendant of its own.

How does its category compare?

All LTK devices

LTK Test, Epithelial Ovarian Tumor-Associated Antigen (Ca125): FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · LTK

1in 2024

2007: 12009: 22011: 12015: 22020: 12022: 12023: 12024: 1
2007high 2 (2009) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LTK

Too few LTK 510(k)s in any year since 2007 to give a median.

Recalls per year · LTK

1in 2013

2007: 12010: 32013: 1
2007high 3 (2010) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LTK

4in 2025

2007: 42008: 92009: 312010: 122011: 52012: 332013: 142014: 302015: 112016: 42017: 152018: 82019: 152020: 52021: 22022: 22023: 62024: 62025: 4
2007high 33 (2012) · low 2 (2021)2025

MAUDE reports naming product code LTK, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—14
20080—09
20092—031
20100—312
20111—05
20120—033
20130—114
20140—030
20152—011
20160—04
20170—015
20180—08
20190—015
20201—05
20210—02
20221—02
20231—06
20241—06
20250—04
20260—0—

What is it indicated for?

AIA-PACK CA 125 is intended for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of CA 125 in human serum on TOSOH AIA System analyzers. AIA-PACK CA 125 is to be used as an aid in monitoring response to therapy for patients with epithelial ovarian cancer. Serial testing for patient CA 125 assay values should be used in conjunction with other clinical methods used for monitoring ovarian cancer.

Indications for use read by OCR from a scanned FDA 510(k) statement, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K990431: Aia-Pack CA 125.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K990431

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026